EZH2 and cholangiocarcinoma: Sp1 activated the transcription of SPRY4‐IT1, a lncRNA that functioned as a scaffold to recruit DNA methyltransferase 1 (DNMT1), enhancer of zeste homolog 2 (EZH2), and lysine‐specific demethylase 1 (LSD1) to suppress the expression of large tumor suppressor 2 (LATS2; a kinase responsible for phosphorylate and inactivated YAP), and exert oncogenic activity in cholangiocarcinoma (CCA) [17].